Genzyme/Isis Gear Up For Long-awaited Kynamro Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme said it is ready to deliver product, but complying with the REMS that helped pave the way for approval is a time-limiting factor for launching the familial hypercholesterolemia drug. Drug will be priced at $176,000 per year, significantly lower than Aegerion’s competing Juxtapid.
You may also be interested in...
Isis Preps To Advance Two Drugs To Phase III In Rare Diseases
Isis will target its APOCIII candidate to treat extremely and severely high triglycerides first, then move to broader populations. The strategy harkens back to the plan for cholesterol drug Kynamro, which has had a slow launch.
Financings Of The Fortnight: Bluebird IPO Could Provide Validation For Gene Therapy As A Modality
During a year in which biotech IPOs have taken off, the bluebird bio issue calls for special attention. Plus news on recent financings by Quintiles, Portola, Isis and Lumena.
Flush With Cash And Partnered Up, Regulus Turns To Clinical Execution: An Interview With CEO Kleanthis Xanthopoulos
Regulus notched two partnerships and an IPO in 2012, putting it on firmer financial ground. Now, as it transitions to executing on its partnerships and pushing ahead with its internal programs, its task is to demonstrate the clinical utility of its miRNA compounds.